18 May 2017 15:17
For immediate release | 18 May 2017 |
ABCAM PLC
("Abcam" or "the Company")
Application for admission to trading
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that further to the acquisition of AxioMx, Inc. in November 2015 and the achievement of certain performance milestones announced earlier today, an application has been made to the London Stock Exchange for 173,297 new ordinary shares of 0.2p each in the Company each with voting rights to be admitted to trading on AIM. Admission is expected to take place on 23 May 2017.
Following the admission of the above shares, the Company's issued ordinary share capital will comprise 204,182,714 ordinary shares of 0.2p each with voting rights. This figure may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Abcam under the FCA's Disclosure and Transparency Rules.
For further information please contact:
Abcam | |
Suzanne Smith, Company Secretary
| + 44 (0) 1223 696 000 |
J.P.Morgan Cazenove - Nominated Adviser & Corporate Broker | |
James Mitford / Chris Cargill | + 44 (0) 20 7742 4000 |
FTI Consulting |
|
Ben Atwell / Brett Pollard / Natalie Garland-Collins | + 44 (0) 20 3727 1000 |
Notes for editors:
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.
By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Abcam's twelve locations are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and www.abcamplc.com